iShares US Pharma

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Bristol Myers Squibb Partners with Anthropic and Tempus AI to Build AI Drug Development Collaboration

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

Pfizer and Sarah Cannon Institute Announce Strategic Oncology Research Collaboration

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Bristol Myers Squibb Provides Anthropic's Claude to 30,000 Employees

Marble Harbor Increases Pfizer Stake by 13.4% to $11.1M as Q4 Earnings Beat Expectations

Pfizer Advances Key Pediatric Pneumococcal Vaccine Project Following Strong Phase II Results

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

Elanco EVP Rajeev A. Modi Buys Nearly 5,000 Shares, Total Holdings Rise to Approx 160k

Elanco CEO Jeffrey N. Simmons Buys 4,971 Shares and Receives 142 DSUs

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UBS Upgrades Jazz Pharma to Buy, Raises Price Target to $307

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

Micware

BiomX

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

MRNA

ROIV

ARKG

LABU

Roivant Sciences reported significant clinical and financial developments in Q4 2025, including high response rates in the IMVT-1402 RA study and breakthrough therapy designation for brepocitinib in cutaneous sarcoidosis. The company anticipates receiving $950 million from a $2.25 billion Moderna settlement in July, enhancing its cash position of $4.3 billion. Preparations for the commercial launch of brepocitinib in dermatomyositis are on track for September, while ongoing studies for Mosliciguat show promising results in pulmonary hypertension.

Motley Fool

Moderna

Roivant Sciences

VG Health

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Roivant (ROIV) Q4 2025 Earnings Transcript

SLXN

HCWB

MTVA

SBIO

On Wednesday, HCW Biologics surged 126.4% to $2.4, following its Q1 earnings report. Other gainers included Silexion Therapeutics (+77.58%), MetaVia (+54.78%), and Immunovant (+36.2%). Conversely, Wellgistics Health fell 28.6% to $0.12, with Sunshine Biopharma and GlucoTrack also declining significantly. The market values of these companies vary, with Immunovant holding a market cap of $5.3 billion.

benzinga_article

Immunovant

ALPS Medical Breakthrough

VanEck Pharmaceutical ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Invesco Pharmaceuticals ETF

SPDR Pharmac

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Nasdaq Biotechnology ETF

Quantum Cyber NV

Wellgistics Health

Sunshine Biopharma

GlucoTrack

Lakewood-Amedex Biotherapeutics

Purple Biotech

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Mainz Biomed NV

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Intraday Session

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

Barchart Option

InMed Pharmaceuticals

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

RLAY

Relay Therapeutics' drug zovegalisib shows promise in treating vascular anomalies, achieving a 60% response rate in a mid-stage trial. Most patients reported symptom improvement, and the drug appears safe for chronic use. Relay's shares rose by 10% following the announcement. Analysts predict zovegalisib could generate $2.8 billion in peak annual sales, highlighting its potential as a leading treatment in this area. Further testing is planned, with results expected by year-end.

biopharmadive

Relay Therapeutics

NOVARTIS AG

Novartis AG

Relay drug shows early promise against rare blood vessel diseases

MetaVia shares are trading higher after the company announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel.

LLYX

ELIL

The 2026 Milliman Medical Index reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase—the highest in over a decade. Key drivers include a 14.8% rise in pharmacy costs, influenced by GLP-1 drugs, and a 7.5% increase in outpatient facility costs. The report highlights the role of AI in optimizing billing processes, contributing to this significant cost growth.

- The Milliman Medical Index for 2026 reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase, the highest in over a decade.  
- Contributing factors include a 14.8% rise in pharmacy costs driven by GLP-1 drugs and high-cost specialty medications, alongside a 7.5% increase in outpatient facility costs.  
- Additionally, the introduction of artificial intelligence in billing processes is noted as a significant new factor in these rising costs.

MorningStar

Eli Lilly

Novo Nordisk AS

SPDR S&P Health

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Long NVO ETF

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

PODD

Eli Lilly (LLY) has a forward P/E of 25.4, higher than the healthcare sector and S&P 500 averages, justified by strong growth projections. Insulet (PODD) also in healthcare, has a lower forward P/E but higher CAGR projections for revenue and EPS compared to Lilly.

Dow Jones

Insulet

S&P 500

These 15 S&P 500 stocks could be contrarian -2-

510660

588130

512290

159992

Flow Pharma, Inc. announced that its U.S. Patent application for a broad-spectrum Ebola treatment has been allowed. The treatment utilizes siltuximab, effective against all Ebola strains, and is delivered via the proprietary FlowVax™ microsphere technology. The company aims for FDA approval to provide a universal Ebola therapy. Flow Pharma also develops vaccines for various diseases using its synthetic microsphere platform, which is designed for biodefense and cancer immunotherapy applications.

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy

Engage Biologics Inc. has been acquired by Eli Lilly and Company for up to $202 million to enhance the development of non-viral genetic medicines. Engage's Tethosome platform aims to improve DNA delivery's potency, tolerability, and redosability. The acquisition combines Engage's innovative technology with Lilly's extensive genetic medicine capabilities, promising to accelerate the development of new genetic therapies.

Fidelity

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

Roivant Sciences (NASDAQ:ROIV) reported strong Q4 2026 results, highlighting a $2.25 billion settlement with Moderna and advancements in its drug pipeline. The company has $4.3 billion in cash, no debt, and is actively repurchasing shares. Key developments include promising data from the 1402 study for rheumatoid arthritis and plans to launch Brepocitinib for dermatomyositis by September, pending FDA approval. Roivant remains optimistic about its pipeline and upcoming milestones in various therapeutic areas.

Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript

iShares US Pharma(IHE.US)

Roivant (ROIV) Q4 2025 Earnings Transcript

12 Health Care Stocks Moving In Wednesday's Intraday Session

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

Relay drug shows early promise against rare blood vessel diseases

MetaVia shares are trading higher after the company announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel.

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

These 15 S&P 500 stocks could be contrarian -2-

Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript